1. Home
  2. AIRE vs MBRX Comparison

AIRE vs MBRX Comparison

Compare AIRE & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo reAlpha Tech Corp.

AIRE

reAlpha Tech Corp.

HOLD

Current Price

$2.12

Market Cap

11.3M

Sector

N/A

ML Signal

HOLD

Logo Moleculin Biotech Inc.

MBRX

Moleculin Biotech Inc.

HOLD

Current Price

$2.41

Market Cap

13.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIRE
MBRX
Founded
2021
2015
Country
United States
United States
Employees
54
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.3M
13.1M
IPO Year
2023
2016

Fundamental Metrics

Financial Performance
Metric
AIRE
MBRX
Price
$2.12
$2.41
Analyst Decision
Buy
Strong Buy
Analyst Count
3
2
Target Price
$1.30
$61.00
AVG Volume (30 Days)
151.8K
265.7K
Earning Date
04-28-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
60.34
N/A
EPS
N/A
N/A
Revenue
$4,518,498.00
N/A
Revenue This Year
$129.06
N/A
Revenue Next Year
$83.72
N/A
P/E Ratio
N/A
N/A
Revenue Growth
376.42
N/A
52 Week Low
$0.14
$0.25
52 Week High
$3.98
$7.98

Technical Indicators

Market Signals
Indicator
AIRE
MBRX
Relative Strength Index (RSI) 51.49 47.30
Support Level $0.31 $2.24
Resistance Level $3.98 $2.64
Average True Range (ATR) 0.24 0.21
MACD -0.08 0.00
Stochastic Oscillator 27.84 42.69

Price Performance

Historical Comparison
AIRE
MBRX

About AIRE reAlpha Tech Corp.

ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are Homebuying Services and the Technology Services segment.

About MBRX Moleculin Biotech Inc.

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

Share on Social Networks: